“Real-World Effectiveness and Safety of Nemolizumab in Moderate-to-Severe Atopic Dermatitis: A Phase IV, Prospective, Non-Interventional Study Design From RE-UNITE-AD (NCT06988605)”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s746, https://doi.org/10.25251/nq0ynj58.